Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cerebrotendinous xanthomatosis.

V M Berginer1, G Salen, S Shefer

  • 1Department of Neurology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Neurologic Clinics
|February 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malabsorption in intestinal scleroderma. Relation to bacterial flora and treatment with antibiotics.

Annals of internal medicine·2013
Same author

Efficacy and safety of ezetimibe 40 mg vs. ezetimibe 10 mg in the treatment of patients with homozygous sitosterolaemia.

International journal of clinical practice·2008
Same author

Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia.

Circulation·2004
Same author

Normal cognition and behavior in a Smith-Lemli-Opitz syndrome patient who presented with Hirschsprung disease.

American journal of medical genetics. Part A·2003
Same author

Two novel mutations in the sterol 27-hydroxylase gene causing cerebrotendinous xanthomatosis.

Clinical genetics·2002
Same author

Developmental sensitivity of associative learning to cholesterol synthesis inhibitors.

Behavioural brain research·2002
Same journal

Sports Neurology.

Neurologic clinics·2026
Same journal

Sports-Related Peripheral Nerve Injuries.

Neurologic clinics·2026
Same journal

Active Rehabilitation and Return to Play in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Autonomic Assessment and Management in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Management of Vestibular Symptoms in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Neuropsychological Assessment in Sport-Related Concussion: Evidence, Controversies, and Clinical Applications.

Neurologic clinics·2026
See all related articles

Cerebrotendinous xanthomatosis (CTX) is a rare lipid disorder. Chenodeoxycholic acid replacement therapy effectively reduces cholestanol levels and improves neurological function in patients with CTX.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder.
  • It results from mutations in the CYP27A1 gene, affecting bile acid synthesis.
  • Characterized by cholestanol accumulation in tissues, leading to neurological and systemic issues.

Purpose of the Study:

  • To investigate the efficacy of chenodeoxycholic acid (CDCA) replacement therapy in managing CTX.
  • To assess the impact of CDCA on cholestanol levels and clinical manifestations.

Main Methods:

  • Administration of chenodeoxycholic acid (750 mg/day) to patients with CTX.
  • Monitoring of plasma cholestanol concentrations.
  • Clinical assessment of neurological function, xanthomas, and cataracts.

Related Experiment Videos

Main Results:

  • CDCA therapy significantly suppressed abnormal bile acid synthesis.
  • Elevated plasma and tissue cholestanol levels were reduced.
  • Patients showed improvement in neurological dysfunction and regression of xanthomas.

Conclusions:

  • Chenodeoxycholic acid replacement therapy is a viable treatment for Cerebrotendinous xanthomatosis.
  • This therapy normalizes bile acid synthesis, reduces cholestanol burden, and ameliorates clinical symptoms.